Last reviewed · How we verify

NCT05172076: CAASP2

COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor-2

Completed Last updated 29 November 2023
What this trial tests

trial in Anxiety State in 276 participants. Completed in 31 July 2023.

Timeline
1 January 2022
Primary endpoint
31 July 2022
31 July 2023

Quick facts

Lead sponsorMartin-Luther-Universität Halle-Wittenberg
StatusCompleted
Study typeOBSERVATIONAL
Enrollment276
Start date1 January 2022
Primary completion31 July 2022
Estimated completion31 July 2023
Sites2 locations across Germany

Conditions studied

Sponsor

Martin-Luther-Universität Halle-Wittenberg — full company profile →

Who can join

18 and older, female only, with Anxiety State. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Capture of anxiety for anomalies, stillbirth and preterm labor of pregnant women during COVID-19 pandemia

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety State

Currently open trials in the same condition.

Other Martin-Luther-Universität Halle-Wittenberg trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing